Latest Content

T-DXd plus pertuzumab improved PFS and DOR across HER2+ breast cancer subgroups, regardless of prior therapy or PIK3CA mutation status.

Disitamab vedotin/toripalimab improved PFS and OS vs chemotherapy in HER2-expressing advanced urothelial carcinoma, per phase 3 RC48-C016 data.

Treatment for patients with R/R multiple myeloma should be based on the individual patient and their history, said Lisa Hwa Christenson, DNP, APRN, CNP.

Among lymphoma survivors, a multidisciplinary intervention program had a beneficial effect on fatigue and aspects of health-related quality of life.

Twenty-year follow-up demonstrated continued imatinib efficacy in advanced GIST with doubled median overall survival.

Using gender-neutral language is the first step in making a safe space for LGBTQIA+ patients with cancer, explained Al Asante-Facey, PA, MBA.

Supervised physical activity, while feasible, was not shown to affect quality of life or fatigue in patients with metastatic cancer.

Paola Gonzalez, MPAS, PA-C, explains how third-party vendors shape insurance guidelines and what oncology APPs should know when navigating peer-to-peer reviews.

Korie Bigbee, DNP, explains the necessity of survivorship care and how to enact changes to make it more accessible to patients with cancer.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.

Adding platinum-based chemotherapy to osimertinib improved overall survival vs osimertinib alone in EGFR-mutated NSCLC, even in high-risk subgroups.

Sevabertinib demonstrated robust, durable responses and manageable safety in both treatment-naive and pretreated patients with HER2-mutant advanced NSCLC.